NZ335382A - Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases - Google Patents
Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseasesInfo
- Publication number
- NZ335382A NZ335382A NZ335382A NZ33538297A NZ335382A NZ 335382 A NZ335382 A NZ 335382A NZ 335382 A NZ335382 A NZ 335382A NZ 33538297 A NZ33538297 A NZ 33538297A NZ 335382 A NZ335382 A NZ 335382A
- Authority
- NZ
- New Zealand
- Prior art keywords
- terminus
- amino acids
- human
- linker
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A multi-functional chimeric hematopoietic protein comprising an amino acid sequence of the formula: R1-L1-R2, R2-L1-R1, R1-R2 or R2-R1 Wherein R1 and R2 are independently selected from the group consisting of; (I) A human EPO receptor agonist polypeptide, comprising a modified EPO as shown in Sequence ID 464, wherein 1-6 amino acids from the N-terminus and/or 1-5 from the C-terminus are optionally deleted. The N-terminus is joined to the C-terminus directly or through a linker (L2). (II) A human stem cell factor receptor agonist polypeptide comprising a modified stem cell factor as shown in Sequence ID 465, wherein 1-23 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (III) A human flt-3 receptor agonist polypeptide comprising a modified flt-3 ligand as shown in Sequence ID 466, wherein 1-7 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (IV) A human G-CSF polypeptide comprising a modified human G-CSF as shown in Sequence ID 858, wherein Xaa may be replaced with any of the disclosed amino acids and 1-11 amino acids and/or 1-5 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (V) A human IL-3 polypeptide comprising a modified human IL-3 as shown in Sequence ID 859 whereupon the modified IL-3 is circularly permuted, wherein Xaa may be replaced with any of the disclosed amino acids and 1-14 amino acids and/or 1-15 amino acids are optionally deleted from the C-terminus and amino acids 0-44 designated Xaa are different to the corresponding native human IL-3 (1-133). The N-terminus is joined to the C-terminus directly or through a linker (L2). (VI) A human c-mpl ligand polypeptide comprising a modified human c-mpl ligand as shown in Sequence ID 860, wherein Xaa may be replaced with any of the disclosed amino acids. The N-terminus is joined to the C-terminus directly or through a linker (L2). (VII) A human IL-3 polypeptide comprising a modified human IL-3 as shown in Sequence ID 859, wherein Xaa may be replaced with any of the disclosed amino acids and 1-14 amino acids and/or 1-15 amino acids are optionally deleted from the C-terminus and amino acids 0-44 designated Xaa are different to the corresponding native human IL-3 (1-133). The N-terminus is joined to the C-terminus directly or through a linker (L2). (VIII) A factor selected from the group consisting of a colony stimulating factor, a cytokine, a lymphokine, an interleukin and a hematopoietic growth factor; and L1 is a linker capable of linking R1 to R2, with the proviso that R1 and R2 is selected from the polypeptide of the Formula (I), (II) or (III).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2962996P | 1996-10-25 | 1996-10-25 | |
| PCT/US1997/020037 WO1998017810A2 (en) | 1996-10-25 | 1997-10-23 | Multi-functional chimeric hematopoietic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ335382A true NZ335382A (en) | 2001-03-30 |
Family
ID=21850035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ335382A NZ335382A (en) | 1996-10-25 | 1997-10-23 | Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0935663A2 (en) |
| JP (1) | JP2001504689A (en) |
| KR (1) | KR100497423B1 (en) |
| AR (1) | AR010041A1 (en) |
| AU (1) | AU725547B2 (en) |
| BR (1) | BR9713668A (en) |
| CA (1) | CA2268742A1 (en) |
| CZ (1) | CZ295843B6 (en) |
| IL (1) | IL129565A0 (en) |
| NO (1) | NO991948L (en) |
| NZ (1) | NZ335382A (en) |
| PL (1) | PL333023A1 (en) |
| RO (1) | RO120919B1 (en) |
| RU (2) | RU2245887C2 (en) |
| TW (2) | TW200413407A (en) |
| WO (1) | WO1998017810A2 (en) |
| ZA (1) | ZA979607B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2284127A1 (en) * | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Flt3 ligand chimeric proteins |
| BR9905867A (en) * | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Recombinant human erythropoietin-producing cell line and the recombinant human erythropoietin produced by this cell |
| WO2002101047A1 (en) * | 2001-06-12 | 2002-12-19 | Smithkline Beecham Corporation | Method of identifying compounds that modulate epo primary response gene 1, eprg1, activities |
| ATE468862T1 (en) | 2001-07-11 | 2010-06-15 | Maxygen Inc | G-CSF CONJUGATES |
| DE602004023956D1 (en) | 2003-08-18 | 2009-12-17 | Univ California | POLYPEPTIDE DISPLAY LIBRARIES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| JP5137821B2 (en) | 2005-06-01 | 2013-02-06 | マキシジェン， インコーポレイテッド | PEGylated G-CSF polypeptide and method for producing the same |
| US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| WO2007027935A2 (en) | 2005-08-31 | 2007-03-08 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| WO2007098548A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| JP2022527322A (en) * | 2019-03-28 | 2022-06-01 | オリオニス バイオサイエンシズ，インコーポレイテッド | FMS-like tyrosine kinase 3 ligand (FLT3L) -based chimeric protein |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8735991A (en) * | 1990-09-28 | 1992-04-28 | Ortho Pharmaceutical Corporation | Hybrid growth factors |
| US5376367A (en) * | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
| US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| US6057133A (en) * | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
| US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
-
1997
- 1997-10-23 NZ NZ335382A patent/NZ335382A/en unknown
- 1997-10-23 CZ CZ19991323A patent/CZ295843B6/en not_active IP Right Cessation
- 1997-10-23 RU RU99111071/13A patent/RU2245887C2/en not_active IP Right Cessation
- 1997-10-23 JP JP51975498A patent/JP2001504689A/en not_active Abandoned
- 1997-10-23 BR BR9713668-9A patent/BR9713668A/en not_active Application Discontinuation
- 1997-10-23 RO RO99-00480A patent/RO120919B1/en unknown
- 1997-10-23 IL IL12956597A patent/IL129565A0/en unknown
- 1997-10-23 CA CA002268742A patent/CA2268742A1/en not_active Abandoned
- 1997-10-23 EP EP97946495A patent/EP0935663A2/en not_active Withdrawn
- 1997-10-23 WO PCT/US1997/020037 patent/WO1998017810A2/en not_active Application Discontinuation
- 1997-10-23 KR KR10-1999-7003635A patent/KR100497423B1/en not_active IP Right Cessation
- 1997-10-23 AU AU51652/98A patent/AU725547B2/en not_active Ceased
- 1997-10-23 PL PL97333023A patent/PL333023A1/en unknown
- 1997-10-27 ZA ZA979607A patent/ZA979607B/en unknown
- 1997-10-27 TW TW093111460A patent/TW200413407A/en unknown
- 1997-10-27 TW TW086116018A patent/TW591035B/en not_active IP Right Cessation
- 1997-10-28 AR ARP970104979A patent/AR010041A1/en unknown
-
1999
- 1999-04-23 NO NO991948A patent/NO991948L/en not_active Application Discontinuation
-
2005
- 2005-02-24 RU RU2005105360/13A patent/RU2005105360A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA979607B (en) | 1999-04-28 |
| CA2268742A1 (en) | 1998-04-30 |
| NO991948L (en) | 1999-06-23 |
| CZ132399A3 (en) | 1999-12-15 |
| KR20000052812A (en) | 2000-08-25 |
| WO1998017810A2 (en) | 1998-04-30 |
| AR010041A1 (en) | 2000-05-17 |
| RO120919B1 (en) | 2006-09-29 |
| CZ295843B6 (en) | 2005-11-16 |
| WO1998017810A3 (en) | 1998-10-15 |
| IL129565A0 (en) | 2000-02-29 |
| TW591035B (en) | 2004-06-11 |
| KR100497423B1 (en) | 2005-07-07 |
| RU2245887C2 (en) | 2005-02-10 |
| EP0935663A2 (en) | 1999-08-18 |
| JP2001504689A (en) | 2001-04-10 |
| RU2005105360A (en) | 2006-08-10 |
| TW200413407A (en) | 2004-08-01 |
| AU725547B2 (en) | 2000-10-12 |
| BR9713668A (en) | 2000-03-08 |
| AU5165298A (en) | 1998-05-15 |
| PL333023A1 (en) | 1999-11-08 |
| NO991948D0 (en) | 1999-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ335382A (en) | Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases | |
| BR9506733A (en) | Multivarian il-3 hematopoiesis fusion protein | |
| RU2007132188A (en) | CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS WITH A MODIFIED HALF-TIME IN VIVO | |
| NZ333999A (en) | GnRH-leukotoxin chimeric proteins for use in vaccines | |
| WO1994012639A3 (en) | Interleukin-3 (il-3) mutant polypeptides | |
| CA2380331A1 (en) | Multiple cytokine-antibody complexes | |
| CA2190371A1 (en) | Receptor for oncostatin m | |
| HK1017261A1 (en) | Hybrid with interferon-alpha and an immunoglobulinfc linked through a non-immunogenic peptide. | |
| EP1881070A3 (en) | Human cytokine as ligand of the zalpha receptor and uses thereof | |
| EP0557418A4 (en) | A -g(b)-type transforming growth factor | |
| GR860509B (en) | Biologically active proteins and a method for their production | |
| PT863155E (en) | BLENDING OF T-CELL PROLIFERATION USING PEPTIDIC FRAGMENTS OF MYELINE BASIC PROTEIN | |
| JPS55143945A (en) | Novel polypeptide | |
| AU726663B2 (en) | SCF analog compositions and methods | |
| ATE140008T1 (en) | POLYPEPTIDE | |
| AU2199895A (en) | Covalent dimers of kit ligand and flt-3/flk-2 ligand | |
| IL72489A0 (en) | Preparation of polypeptides having an amide carboxyl terminal end | |
| DK0446315T3 (en) | Process for Preparing PAI-2 | |
| Leong et al. | Cloning and expression of the cDNA for bovine granulocyte-macrophage colony-stimulating factor | |
| Zav'yalov et al. | Theoretical conformational analysis of a family of α-helical immunocytokines | |
| CA2083286A1 (en) | Recombinant fibrinogenases, preparation and use thereof | |
| Kishimoto et al. | Molecular structure and immunological function of human B cell differentiation factor (BSF2) | |
| WO2001029223A3 (en) | Type i membrane protein ztsl1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |